In this issue:
- Cumulative effects of therapies on disability in RRMS
- Prediction of MS outcomes when switching to ocrelizumab
- Rapid and sustained B cell depletion with subcutaneous ofatumumab in relapsing MS
- MENACTRIMS practice guideline for COVID-19 vaccination in pwMS
- Humoral and T-cell responses to COVID-19 vaccine in pwMS treated with ocrelizumab
- Association of DMT and anti-CD20 infusion timing with humoral response to SARS-CoV-2 vaccines
- Depression in MS
- Treatment escalation vs immediate initiation of highly effective treatment for RRMS
- Safety and efficacy of the oral BTK inhibitor tolebrutinib in relapsing MS
- Epilepsy as a predictor of disease progression in MS
Please login below to download this issue (PDF)